Generic Pharmaceuticals Contract Manufacturing Market Size, Trends, Demand and Future Growth

Generic Pharmaceuticals Contract Manufacturing Market Size- By Drug Type, By Product, By Route of Administration, By Application- Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Generic Pharmaceuticals Contract Manufacturing Market Size- By Drug Type, By Product, By Route of Administration, By Application- Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Published: Dec 2022 Report ID: PHAR2215 Pages: 1 - 244 Formats*:     
Category : Pharmaceutical
Global Generic Pharmaceuticals Contract Manufacturing Market Overview

According to SPER Market Research, the Global Generic Pharmaceuticals Contract Manufacturing Market is estimated to reach USD 121.42 billion by 2032 with a CAGR of 6.04%.

The industry's growth is being driven by the advantages of outsourcing in terms of cost and time savings. A generic medication is a prescription medication that shares the same chemical components as a medication that was first covered by a chemical patent. Following the expiration of the patents on the original medications, generic medications may be sold. Generics function as well in terms of the medical profile because the active chemical component is the same. The active pharmaceutical ingredient (API) in a generic medication is the same as that in the brand-name medication, but there may be differences in the manufacturing method, formulation, excipients, colour, taste, and packaging. Around the world, a sizable population is afflicted with chronic illnesses. For instance, according to the CDC, 6 out of 10 persons in the U.S. have at least one chronic condition, and 4 out of 10 have two or more. Long-term treatment is necessary for chronic diseases. The demand for cost-effective generic drugs for the treatment of chronic diseases is rising as a result of the high cost of pharmaceuticals. It is anticipated that the presence of numerous important firms in this area will have a substantial impact on its development. 

Impact of COVID-19 on the Global Generic Pharmaceuticals Contract Manufacturing Market
This is anticipated to boost the industry's expansion following the pandemic. The regulatory approval process for generic medications has improved. Advancements in this sector are anticipated to benefit the production of generic medications and, as a result, assist the expansion of the sector. The Japanese government is continually working to develop the nation's market for generic medications. The government is also urging medical institutions to promote the use of generic medications and is taking steps to increase the availability of generics in the nation. In the upcoming years, this is anticipated to enhance CMO operations for generic drugs. The amount spent globally on medications is also increasing. The region's growth is further supported by the increasing tendency of pharmaceutical businesses in the area to outsource non-core activities like manufacturing.




Scope of the Report:
 Report Metric Details
 Market size available for years 2019-2032
 Base year considered 2021
 Forecast period 2022-2032
 Segments coveredBy Drug Type, By Product, By Route of Administration, By Application
 Regions coveredAsia Pacific, Europe, Middle East and Africa,North America, Latin America
 Companies CoveredAcme Generics Pvt Ltd., Alcami Corp. Inc., Aurobindo Pharma, Cambrex Corp., Catalent, Inc, Curia Global, Inc., Jubilant Generics Ltd., Metric Contract Services, Pfizer CentreOne, Recipharm Ab, Siegfried Holding AG, Syngene International Limited
Global Generic Pharmaceuticals Contract Manufacturing Market Segmentation:
1. By Drug Type: 
  • Branded
  • Unbranded
2. By Product: .
  • API
  • Drug Product
3. By Route of Administration:
  • Oral
  • Parenteral
  • Topical
  • Others
4. By Application: 
  • Anticoagulants
  • Antidiabetic
  • Cardiovascular
  • HIV antivirals
  • Immunology
  • Neurology
  • Oncology
  • Pain
  • Respiratory
  • Others
5. By Region:
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • North America
  • South America

Key Topics Covered in the Report:

  • Size of Global Generic Pharmaceuticals Contract Manufacturing Market (FY’2019-FY’2032)
  • Overview of Global Generic Pharmaceuticals Contract Manufacturing Market
  • Segmentation of Global Generic Pharmaceuticals Contract Manufacturing Market By Drug Type (Branded, Unbranded)
  • Segmentation of Global Generic Pharmaceuticals Contract Manufacturing Market By Product (API, Drug Product)
  • Segmentation of Global Generic Pharmaceuticals Contract Manufacturing Market By Route of Administration (Oral, Parenteral, Topical, Others)
  • Segmentation of Global Generic Pharmaceuticals Contract Manufacturing Market By Application (Anticoagulants, Antidiabetic,Cardiovascular, HIV antivirals, Immunology, Neurology, Oncology, Pain, Respiratory, Others)
  • Statistical Snap of Global Generic Pharmaceuticals Contract Manufacturing Market
  • Growth Analysis of Global Generic Pharmaceuticals Contract Manufacturing Market
  • Problems and Challenges in Global Generic Pharmaceuticals Contract Manufacturing Market
  • Competitive Landscape in the Global Generic Pharmaceuticals Contract Manufacturing Market
  • Impact of COVID-19 and Demonetization on Global Generic Pharmaceuticals Contract Manufacturing Market
  • Details on Recent Investment in Global Generic Pharmaceuticals Contract Manufacturing Market
  • Competitive Analysis of Global Generic Pharmaceuticals Contract Manufacturing Market
  • Major Players in the Global Generic Pharmaceuticals Contract Manufacturing Market
  • SWOT Analysis of Global Generic Pharmaceuticals Contract Manufacturing Market
  • Global Generic Pharmaceuticals Contract Manufacturing Market Future Outlook and Projections (FY’2019-FY’2032)
  • Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
 
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2  Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3  Data triangulation
 
3. Executive Summary
 
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges 
4.2. COVID-19 Impacts of the Global Generic Pharmaceuticals Contract Manufacturing Market 
 
5. Market variables and outlook
5.1. SWOT analysis 
5.1.1 Strengths 
5.1.2 Weaknesses 
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis 
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape 
5.2.4 Technological landscape 
5.2.5 Environmental landscape 
5.2.6 Legal landscape 
5.3. PORTER’S five forces analysis 
5.3.1 Bargaining power of suppliers 
5.3.2 Bargaining power of Buyers 
5.3.3 Threat of Substitute 
5.3.4 Threat of new entrant 
5.3.5 Competitive rivalry
5.4.Heat map analysis

6. Competitive Landscape
6.1. Global Generic Pharmaceuticals Contract Manufacturing Base Distribution, Sales Area, Product Type 
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Generic Pharmaceuticals Contract Manufacturing
 
7. Global Generic Pharmaceuticals Contract Manufacturing Market, By Drug Type, 2019-2032 (USD Million)
7.1. Branded
7.2. Unbranded

8. Global Generic Pharmaceuticals Contract Manufacturing Market, By Product, 2019-2032 (USD Million)
8.1. API
8.2. Drug Product

9. Global Generic Pharmaceuticals Contract Manufacturing Market, By Route of Administration, 2019-2032 (USD Million)
9.1. Oral
9.2. Parenteral
9.3. Topical
9.4. Others

10. Global Generic Pharmaceuticals Contract Manufacturing Market, By Application, 2019-2032 (USD Million)
10.1. Anticoagulants
10.2. Antidiabetic
10.3. Cardiovascular
10.4. HIV antivirals
10.5. Immunology
10.6. Neurology
10.7. Oncology
10.8. Pain
10.9. Respiratory
10.10. Others

11. Global Generic Pharmaceuticals Contract Manufacturing Market, By Region, 2019-2032 (USD Million)
11.1. Global Generic Pharmaceuticals Contract Manufacturing Size and Market Share by Region (2019-2025)
11.2. Global Generic Pharmaceuticals Contract Manufacturing Size and Market Share by Region (2026-2032)
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Japan
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4 Europe
11.4.1 France
11.4.2 Germany
11.4.3 Italy
11.4.4 Spain
11.4.5 United Kingdom
11.4.6 Rest of Europe
11.5 Middle East & Africa
11.5.1 Kingdom of Saudi Arabia 
11.5.2 United Arab Emirates
11.5.3 Rest of Middle East & Africa
11.6 North America
11.6.1 Canada
11.6.2 Mexico
11.6.3 United States
11.7 Latin America
11.7.1 Argentina
11.7.2 Brazil
11.7.3 Rest of Latin America

12.  Company Profiles
12.1 Acme Generics Pvt Ltd.
12.1.1 Company details
12.1.2 Financial outlook
12.1.3 Product summary
12.1.4 Recent developments
12.2 Alcami Corp. Inc.
12.2.1 Company details
12.2.2 Financial outlook
12.2.3 Product summary
12.2.4 Recent developments
12.3 Aurobindo Pharma
12.3.1 Company details
12.3.2 Financial outlook
12.3.3 Product summary
12.3.4 Recent developments
12.4 Cambrex Corp.
12.4.1 Company details
12.4.2 Financial outlook
12.4.3 Product summary
12.4.4 Recent developments
12.5 Catalent, Inc
12.5.1 Company details
12.5.2 Financial outlook
12.5.3 Product summary
12.5.4 Recent developments
12.6 Curia Global, Inc.
12.6.1 Company details
12.6.2 Financial outlook
12.6.3 Product summary
12.6.4 Recent developments
12.7 Jubilant Generics Ltd.
12.7.1 Company details
12.7.2 Financial outlook
12.7.3 Product summary
12.7.4 Recent developments
12.8 Metric Contract Services
12.8.1 Company details
12.8.2 Financial outlook
12.8.3 Product summary
12.8.4 Recent developments
12.9 Pfizer CentreOne
12.9.1 Company details
12.9.2 Financial outlook
12.9.3 Product summary
12.9.4 Recent developments
12.10 Recipharm Ab
12.10.1 Company details
12.10.2 Financial outlook
12.10.3 Product summary
12.10.4 Recent developments
12.11 Siegfried Holding AG
12.11.1 Company details
12.11.2 Financial outlook
12.11.3 Product summary
12.11.4 Recent developments
12.12 Syngene International Limited
12.12.1 Company details
12.12.2 Financial outlook
12.12.3 Product summary
12.12.4 Recent developments

13. List of Abbreviations

14. Reference Links

15. Conclusion

16. Research Scope

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3


Frequently Asked Questions About This Report
The key players in the market include Companies Covered Acme Generics Pvt Ltd., Alcami Corp. Inc., Aurobindo Pharma, Cambrex Corp., Catalent, Inc, Curia Global, Inc., Jubilant Generics Ltd., Metric Contract Services, Pfizer CentreOne, Recipharm Ab, Siegfried Holding AG, Syngene International Limited.
The North America region is anticipated to have the highest market share in the Generic Pharmaceuticals Contract Manufacturing Market.
The Generic Pharmaceuticals Contract Manufacturing Market is projected to reach USD 121.42 billion by 2032, growing at a CAGR of 6.04% during the forecast period.
The Generic Pharmaceuticals Contract Manufacturing Market grew in market size from 2021. The Market is expected to reach USD 121.42 billion by 2032, at a CAGR of 6.04% during the forecast period.
The Generic Pharmaceuticals Contract Manufacturing Market CAGR of 6.04% during the forecast period.
The Generic Pharmaceuticals Contract Manufacturing Market size is USD 121.42 billion from 2022 to 2032.
The Generic Pharmaceuticals Contract Manufacturing Market segment is Covered By Drug Type, By Product, By Route of Administration, By Application.
The demand for cost-effective generic drugs for the treatment of chronic diseases is rising as a result of the high cost of pharmaceuticals. It is anticipated that the presence of numerous important firms in this area will have a substantial impact on its development.
Not able to find what you are looking for? Need customization in the existing report?
Click Here
PLACE AN ORDER
  • 15% off
     
    $ 4250
  • 20% off
             
    $ 5650
  • 25% off
         
    $ 7450
Pre-Purchase Inquiry
SEND AN INQUIRY
NEED CUSTOMIZATION?
Request Customization
CALL OR EMAIL US
US:
India:
Email:
100% Secure Payment

SPER American Express
SPER VISA
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join Our SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB

SPER

Market Research

We are the leading, full-service global market research and consulting company.

Certificates
iso-1 iso-1
Secure Payments
SPER Payment Options
Connect with us